FDA Approval Alert: The Need-to-Know | Tislelizumab in Metastatic Esophageal Squamous Cell Carcinoma

In March 2024, the FDA approved tislelizumab-jsgr monotherapy for patients with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy.

The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.
Tislelizumab Shows Improvements in Efficacy Vs Chemo in Esophageal Cancer
Video
Apr 5, 2024 8:00 PM
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.
Patients with unresectable or metastatic esophageal squamous cell carcinoma and higher PD-L1 expression may benefit from treatment with tislelizumab, according to Syma Iqbal, MD.
Tislelizumab Approval Adds to Armamentarium in Metastatic Esophageal Cancer
Video
Apr 5, 2024 12:00 PM
Patients with unresectable or metastatic esophageal squamous cell carcinoma and higher PD-L1 expression may benefit from treatment with tislelizumab, according to Syma Iqbal, MD.
Results from the phase 3 RATIONALE 302 trial led to the approval of tislelizumab for patients with unresectable or metastatic esophageal squamous cell carcinoma.
FDA Approves Second-Line Tislelizumab Monotherapy in Esophageal Cancer
Article
Mar 14, 2024 8:51 PM
Results from the phase 3 RATIONALE 302 trial led to the approval of tislelizumab for patients with unresectable or metastatic esophageal squamous cell carcinoma.